About this trial
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Eligibility criteria
Qualifiers
extensive stage small cell lung cancer
Progression after receiving at least one chemotherapy drug treatment in the past;
ECOG score 0-1
c-Myc-driven
Disqualifiers
No measurable lesions
Other severe and persistent diseases or organ system dysfunction;
Women planning pregnancy or men planning family planning;
Women who are pregnant or breastfeeding;
Trial design
Treatments tested in this trial
- Teniposide administration
Treatment groups
Sponsors and collaborators
Shanghai Pulmonary Hospital, Shanghai, China
Lead sponsor
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD
Collaborator